BOVINE SEROLOGICAL RESPONSE TO A RECOMBINANT BPV-1 MAJOR CAPSID PROTEIN VACCINE
BOVINE SEROLOGICAL RESPONSE TO A RECOMBINANT BPV-1 MAJOR CAPSID PROTEIN VACCINE
复制标题
DOI：
10.1159/000150171
复制
发表时间：
1990-11-01
期刊：
影响因子：
4.6
通讯作者：
JENSON, AB
中科院分区：
文献类型：
--
作者：
JIN, XW;COWSERT, L;JENSON, AB
用不同配方的重组BPV-1 DNA疫苗免疫5组荷斯汀×安格斯犊牛（5头犊牛/组）中的4组，所述重组BPV-1 DNA疫苗使用BPV-1主要衣壳：B-半乳糖苷酶融合蛋白作为免疫原。第5组未接种疫苗。接种小牛在试验第0天和第21天接受疫苗接种，所有5组小牛在第56天在两个不同部位分别皮内接种1010个BPV-1颗粒。在试验第3、24、55、77和104天对所有小牛采血，并通过ELISA检测血清与完整和破碎的BPV-1颗粒的反应性。在用BPV-1病毒粒子攻毒时（第56天），20头接种小牛中有19头对破坏的BPV-1粒子呈血清阳性; 20头小牛中有3头的血清与完整的BPV-1病毒粒子反应。到第77天，19头接种小牛中有11头产生了完整BPV-1病毒粒子的抗体滴度;第5组中仅1头小牛产生了针对BPV-1衣壳表位的抗体（一过性）。攻毒后，5组25头小牛中有24头发生皮内纤维瘤，这是本研究的生物学终点。第5组（未接种疫苗、接种对照）中纤维瘤大小似乎增加，而4个接种疫苗组（1-4）的大多数肿瘤大小稳定或减小。尽管小牛产生了纤维瘤，但90%的小牛（第1-4组）产生了针对破坏的BPV-1衣壳蛋白的抗体，而58%的小牛产生了与完整病毒体反应的抗体。接种小牛对完整和破碎的BPV-1颗粒的免疫应答似乎在很大程度上取决于疫苗的各种制剂，特别是佐剂。
Four of five groups of Holestine by Angus calves (5 calves/group) were immunized with different formulations of a recombinant BPV-1 DNA vaccine using a BPV-1 major capsid:B-galactosidase fusion protein as the immunogen. Group 5 was not vaccinated. Vaccinated calves received the vacine on days 0 and 21 of the trial, and calves from all five groups were challenged intradermally with 1010 BPV-1 particles at each of two different sites on day 56. All calves were bled on days 3, 24, 55, 77, and 104 of the trial, and the sera were tested for reactivity with intact and disrupted BPV-1 particles by ELISA. At the time of challenge with BPV-1 virions (day 56), 19 of 20 vaccinated calves were seropositive for disrupted BPV-1 particles; sera from 3 of 20 calves reacted with intact BPV-1 virions. By day 77, 11 of 19 vaccinated calves had developed antibody titers of intact BPV-1 virions; only 1 calf in group 5 developed antibodies (transiently) against BPV-1 capsid epitopes. After challenge, 24 of 25 calves from the five groups developed intradermal fibromas, the biological end point of this study. Fibromas appeared to increase in size in group 5 (unvaccinated, inoculated controls), whereas most tumors from the four vaccinated groups (1-4) stabilized or decreased in size. Although the calves developed fibromas, 90% of calves (in groups 1-4) developed antibodies against disrupted BPV-1 capsid proteins whereas 58% developed antibodies that reacted with intact virions. The immunologic response of vaccinated calves to intact and disrupted BPV-1 particles appeared to be determined in large part by the various formulations of the vaccine, particularly the adjuvant.